Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
6new positions
$2.25Bheld by those funds
AIThis scan
The scan compared 13F-HR filings for the quarter ended June 30, 2026 (filed August 13-14) against the March 31, 2026 window across the five configured funds — Berkshire Hathaway, Bridgewater Associates, Renaissance Technologies, Citadel Advisors, and Two Sigma. All five returned holdings. Roughly 787 CUSIPs passed the base acceleration filter (net buyers > net sellers plus ≥25% aggregate QoQ share growth or ≥2 new positions); 145 of those had Berkshire or Bridgewater as a supporting buyer. After layering market-cap, liquidity, earnings-window (seven-trading-day exclusion), and retail-attention screens, five names survived.
The single most surprising finding is NiSource. Bridgewater built a 1.4-million-share NiSource position from essentially zero (24,531 → 1,410,001 shares) while Renaissance initiated the second-largest add, taking aggregate holdings up 555% QoQ. NiSource is the kind of regulated Midwest utility that rarely draws fast money. The co-occurrence of a slow macro-driven initiation (Bridgewater) and a quant initiation (Renaissance) on the same name suggests both camps found independent evidence of a near-term thesis — most plausibly AI data-center load growth in Indiana and Ohio. Two of the five names (Core & Main and NiSource) are currently trading below the funds' estimated quarter-end entry, meaning retail still has the chance to buy at or below where the four-fund syndicate was buying.
How this scan was run
Per-CUSIP shares were aggregated across each fund's sub-filings (puts excluded; calls counted at the underlying notional). A ticker qualified when net buyers across the five funds exceeded net sellers AND either aggregate QoQ share growth was ≥25% or at least two funds initiated new positions. Single-fund block buys exceeding 80% of the aggregate increase were excluded (Berkshire exempt by policy — none of the final five is a Berkshire block buy anyway). Quant managers (Renaissance, Citadel's market-making book, Two Sigma) were de-weighted when writing theses because their 13F reports only end-of-quarter positions and masks heavy intra-quarter trading. Bridgewater's magnitude of initiations was treated as the primary conviction signal across the final shortlist, since Berkshire's largest adds this quarter (Alphabet, Delta, Macy's, Lennar) were disqualified by the mega-cap or retail-attention rails. CUSIPs resolved to tickers via issuer-name match. No fund failed to return holdings — the Berkshire filing was embedded from the inline MCP response; the other four were parsed from disk after the response exceeded the inline token budget. The 13F lag means these positions were set by June 30, 2026 — the 109-day gap to the scan date is a real limitation; current prices in several names have moved away from the quarter-end average entry estimate.
#1
NI
NiSource Inc.
UtilitiesMkt cap $18.3BNext earnings Nov 2, 2026
Price
$39.55
Est. fund entry
$47.61-16.9%
Shares held
6.07M
Position value
$289.0M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
1.41M
New position
Renaissance Technologies
9.00K
747.3K
+8203.3%
Citadel Advisors
854.3K
3.83M
+348.0%
Two Sigma Investments
62.7K
85.3K
+36.0%
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days7 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
The strongest signal in this scan. Bridgewater's 1.4M-share NiSource initiation from essentially zero is highly uncharacteristic for a macro fund — it typically holds utilities only as yield proxies at the index weight, not as discretionary builds. Pair that with Renaissance going from 9,000 to 747,300 shares, and you have independent fundamental and quant conviction converging on the same regulated Midwest utility (NIPSCO electric, Columbia Gas across IN/OH/PA/VA/KY). The under-recognized catalyst is AI data-center load growth in Indiana (Microsoft, Google, Meta have all announced sites in NiSource's service territory) and the regulatory window to monetize that capex at the 2027 rate case. The stock trades at ~16x forward EPS, roughly a one-point discount to pure-regulated utility comps despite a visibly accelerating demand curve.
What would prove it wrong
Regulatory lag on data-center-related capex recovery is real — rate cases take 12–18 months in these jurisdictions. The stock is already 20% below the fund's estimated entry, which could mean they are wrong or already adding more at lower levels; the 13F cannot tell us which. A sharp drop in long rates would compress utility multiples broadly.
#2
CNM
Core & Main, Inc.
IndustrialsMkt cap $7.8BNext earnings Dec 8, 2026
Price
$40.35
Est. fund entry
$48.23-16.3%
Shares held
2.67M
Position value
$129.0M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
29.4K
New position
Renaissance Technologies
814.1K
1.41M
+73.0%
Citadel Advisors
93.1K
1.20M
+1191.1%
Two Sigma Investments
—
34.0K
New position
Retail attention 4 of 4 signals quiet
Google Trends9/100quiet
News, 30 days4 articlesquiet
Call/put OI1.40quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Specialty distributor of waterworks and underground infrastructure (fire protection, HDPE pipe, storm/sewer) to municipalities and contractors — the kind of business that compounds through cycles because the installed base must be maintained. Both Bridgewater and Two Sigma initiated new positions while Citadel scaled its stake 12x. Core & Main reaffirmed FY2026 guidance of $7.8–7.9B revenue and $950–$980M adjusted EBITDA on the September print; shares still sold off because gross margins compressed on destocking at municipal customers. Funds are treating that as transitory. The under-priced catalyst is the backlog of federal IIJA water-infrastructure dollars that get obligated in 2027 — Core & Main is the pass-through for roughly 15% of US municipal water-system spend.
What would prove it wrong
A sharper housing downturn would hit the residential half of the mix. Pricing pressure from PVC and ductile-iron pipe commodity moves can swing a quarter badly. Buyout speculation is background noise here (Clayton Dubilier previously owned it) — a leaked bid attempt would create resale overhang if it falls through.
#3
ZTS
Zoetis Inc.
Health CareMkt cap $33.5BNext earnings Nov 5, 2026
Price
$75.00
Est. fund entry
$71.86+4.4%
Shares held
5.64M
Position value
$405.0M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
50.7K
134.2K
+164.5%
Renaissance Technologies
252.0K
1.40M
+456.9%
Citadel Advisors
774.8K
3.69M
+376.3%
Two Sigma Investments
159.8K
410.6K
+157.0%
Retail attention 4 of 4 signals quiet
Google Trends19/100quiet
News, 30 days11 articlesquiet
Call/put OI1.60quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
The highest-conviction convergence in the scan: four funds all boosted Zoetis positions by 150%+ in the same quarter, taking aggregate holdings up 356% QoQ. Bridgewater's +164% is particularly notable — Dalio's team rarely leans into single-stock health-care names at this magnitude. The timing fits a classic 'buy the guidance cut' play: Zoetis reduced its 2026 outlook in August citing weak companion-animal demand and FX, which drove the stock to a 52-week low near $71, and the funds appear to have bought into that drawdown. The thesis retail hasn't re-priced: companion-animal demand softness is a 2026 consumer-spending phenomenon that reverses as pet-visit comparisons ease in 1H 2027, and Zoetis's pricing power on prescription-only parasiticides and dermatology franchises is intact.
What would prove it wrong
If companion-animal volumes stay soft into 2027, consensus 2027 EPS has to come down and the valuation re-rate thesis fails. FX is a persistent drag on a USD-reporting multinational. Librela adverse-event litigation remains an unresolved overhang that could resurface.
#4
MDT
Medtronic plc
Health CareMkt cap $118.0BNext earnings Nov 17, 2026
Price
$92.10
Est. fund entry
$78.23+17.7%
Shares held
13.1M
Position value
$1.02B
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
255.2K
482.5K
+89.0%
Renaissance Technologies
—
3.17M
New position
Citadel Advisors
2.45M
6.20M
+153.1%
Two Sigma Investments
626.9K
3.24M
+417.0%
Retail attention 4 of 4 signals quiet
Google Trends22/100quiet
News, 30 days12 articlesquiet
Call/put OI1.50quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Renaissance opened a new 3.17M-share Medtronic position while Bridgewater nearly doubled its existing stake and Citadel added +153%. Aggregate shares across the four funds rose +293% QoQ, and the stock has subsequently rallied from an ~$78 average entry to $92 — so this is a signal that is partially playing out, with more road ahead per the funds' continued ownership. Medtronic has traded at a persistent ~14x forward EPS versus a 10-year median of ~17x since its Hugo surgical-robot FDA submission timeline slipped in 2025. The spring 2027 PMA decision window plus the planned diabetes-business separation (expected to close in 1H 2027) are two discrete rerating catalysts the market is still discounting heavily. The non-obvious piece: Hugo's PMA, if granted, puts Medtronic back in the robotic-surgery conversation with Intuitive after a decade of being written off.
What would prove it wrong
Hugo PMA could slip again, and each slip costs multiple points of multiple. CMS pricing on cardiac rhythm management and spine has structural downside. If the diabetes separation structure disappoints on tax or capital-return terms, the sum-of-parts thesis gets reset.
#5
OSCR
Oscar Health, Inc.
Health CareMkt cap $9.6BNext earnings Nov 4, 2026
Price
$30.00
Est. fund entry
$28.50+5.3%
Shares held
14.3M
Position value
$408.0M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
213.7K
New position
Renaissance Technologies
—
3.28M
New position
Citadel Advisors
5.62M
6.77M
+20.5%
Two Sigma Investments
2.38M
4.05M
+69.9%
Retail attention 3 of 4 signals quiet
Google Trends27/100busy
News, 30 days14 articlesquiet
Call/put OI1.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Bridgewater and Renaissance both initiated this quarter — a notable pairing for a $9.6B near-pure-play ACA marketplace insurer. All four funds added, with aggregate shares across the group up 79% QoQ. The setup is political: the enhanced ACA premium tax credits are scheduled to lapse, which would mechanically compress Oscar's membership. Smart money is positioning for one of two outcomes — tax-credit extension (upside base case), or a less-subsidized market where Oscar's technology-driven acquisition and MLR advantages matter more than they do today, so share gains at the expense of legacy carriers offset volume loss. The catalyst retail is likely under-weighting: 2027 open enrollment data lands November 1 and will materially re-rate the stock up or down.
What would prove it wrong
Enhanced-tax-credit expiration without replacement is a direct multi-point hit to earnings in 2027. The stock is already up roughly 180% from early-2024 lows, so sentiment has lifted substantially — the retail-attention score at 27 is borderline against the ≤25 threshold, meaning the quietness window is closing. OSCR's Google Trends ticks up materially around every open-enrollment period.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.